News from oasmia pharmaceutical ab A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NYSE:AB)

Aug 04, 2015, 07:26 ET
Oasmia logo

Oasmia Pharmaceutical gibt positive Topline-Ergebnisse für Paclical® aus Kopf-an-Kopf-Vergleichsstudie mit Abraxane® bekannt

Vorläufige Studienergebnisse zeigen, dass das wasserlösliche und lösungsmittelfreie Paclical® sowie das auf dem US-Markt...

Aug 04, 2015, 07:00 ET
Oasmia logo

Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Preliminary study findings show that water soluble and solvent free Paclical®, and US-market...

Aug 04, 2015, 05:25 ET

Oasmia Pharmaceutical anuncia resultados positivos de primera línea de Paclical® en su estudio comparativo con Abraxane®

Los descubrimientos preliminares del estudio muestran que Paclical®, soluble en agua y libre de solventes, y Abraxane®, con...

Aug 04, 2015, 03:00 ET
Oasmia logo

Oasmia Pharmaceutical annonce des résultats initiaux positifs pour Paclical® dans le cadre d'une étude de comparaison directe avec Abraxane®

Les résultats préliminaires de l'étude montrent que Paclical®, produit soluble dans l'eau et sans solvant, et Abraxane®,...

Aug 04, 2015, 02:15 ET

Oasmia Pharmaceutical anuncia resultados preliminares positivos para Paclical® en estudio comparativo directo con Abraxane®

Los hallazgos preliminares del estudio muestran que Paclical®, soluble en agua y libre de solventes, y Abraxane®, aprobado...

Aug 04, 2015, 02:15 ET

Oasmia Pharmaceutical anuncia resultados finais positivos para Paclical® em estudos comparativos com Abraxane®

Descobertas em estudos preliminares mostram que Paclical®, solúvel em água e sem solventes, e Abraxane®, remédio aprovado...

Jul 07, 2015, 07:00 ET
Oasmia Pharmaceutical has a product portfolio of significant market potential (PRNewsFoto/Oasmia Pharmaceutical AB)

Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, has filed a registration statement on...

Jul 07, 2015, 07:00 ET
Paccal Vet-CA1 is conditionally approved for treatment of mammary tumors and squamous cell carcinoma (PRNewsFoto/Oasmia Pharmaceutical AB)

Oasmia Pharmaceutical Launches US Brand and Sales Platform

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, today announced that it has established...

Apr 20, 2015, 16:04 ET
Oasmia logo

Paclical®, le produit phare de traitement du cancer d'Oasmia, reçoit l'approbation de commercialisation dans la Fédération de Russie

Oasmia Pharmaceutical AB (« Oasmia ») a annoncé aujourd'hui que Paclical, son produit phare de traitement du cancer, a...

Apr 20, 2015, 16:03 ET
Oasmia logo

Oasmias führendes Krebsprodukt Paclical® erhält Marktzulassung in der Russischen Föderation

Oasmia Pharmaceutical AB ("Oasmia") gab heute bekannt, dass sein führendes Krebsprodukt Paclical vom russischen Gesundheitsministerium die...

Apr 20, 2015, 10:00 ET
Oasmia logo

Oasmia's Lead Cancer Product Paclical® Receives Market Approval in the Russian Federation

Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization in the Russian Federation...

Dec 03, 2013, 03:48 ET

FDA godkänner Oasmias produktionsanläggning i Uppsala

Läkemedelsbolaget Oasmia Pharmaceutical AB (publ) tillkännager idag att bolagets tillverkningsenhet i Uppsala med tillfredställande...

Dec 03, 2013, 02:45 ET

Oasmia meddelar att bolagets tillverkningsenhet i Uppsala har framgångsrikt genomgått FDA-inspektion

Läkemedelsbolaget Oasmia Pharmaceutical AB (publ) tillkännager idag att bolagets tillverkningsenhet i Uppsala med tillfredställande...

Jan 09, 2013, 07:00 ET

Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

Oasmia and Abbott have entered into an exclusive global collaboration agreement with respect to Oasmia's two leading animal health product...

Jan 09, 2013, 07:00 ET

Oasmia och Abbott tecknar globalt samarbetsavtal för den veterinäronkologiska marknaden

Oasmia och Abbott har ingått ett exklusivt globalt samarbetsavtal beträffande Oasmias två första produktkandidater inom Animal...

Jan 07, 2013, 09:25 ET

Oasmia Pharmaceutical and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

Oasmia and Abbott have entered into an exclusive global collaboration agreement with respect to Oasmia's two leading animal health product...

Jul 15, 2010, 02:59 ET

Oasmia Pharmaceutical AB, Sweden - Listing Prospectus: NASDAQ OMX Stockholm

- A Number of Promising New Product Candidates for Cancer Treatment, Within Both Human and Veterinary Oncology ABOUT OASMIA Oasmia is developing...

Apr 14, 2009, 08:02 ET

Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA

Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer....